News

Belhaven Biopharma Announces Groundbreaking Clinical Results for Nasdepi®

Belhaven Biopharma, a leader in innovative treatments for severe allergic reactions, today shared promising results from its Phase 1 clinical trial of…..

Read More

Belhaven Biopharma Achieves Significant Milestones in Advancing Nasdepi®

Belhaven BioPharma has developed a new delivery system for epinephrine that is more efficient, convenient, stable, and less expensive than an EpiPen…..

Read More

NC Biotech Center awards $2.3M in mix of 19 grants, loans

The North Carolina Biotechnology Center awarded 19 grants and loans totaling more than $2.3 million to universities, bioscience companies and ……..

Read More

NC Biotech Center awards nearly $2M in grants, loans to life science firms, universities, groups

The North Carolina Biotechnology Center awarded 21 grants and loans totaling more…

Read More

NC Biotech Center awards $2.3M in mix of 19 grants, loans

Biopharma, a leader in dry powder nasal drug delivery technologies and emergency treatments, is proud to announce that its innovative intranasal epinephrine product……

Read More

Belhaven to Present Phase 1 Data on Needle-Free Epinephrine at ACAAI

Belhaven Biopharma, a leader in nasal drug delivery technologies and emergency allergy care solutions, is set to present new clinical data from its Phase…..

Read More
Synopsis of the progressive study for self-administration of epinepherine.

Evaluation of Drug Product Stability of a Nasal Unit Dose Spray Dried Epinephrine Powder (Nasdepi®)

Belhaven Biopharma, a leader in nasal drug delivery, is excited to unveil promising Phase 1 data on Nasdepi® at an upcoming conference.
Read More

Nasdepi® Named Finalist for 2024 Fierce Innovation Awards

Belhaven Biopharma’s Nasdepi®, a finalist for the 2024 Fierce Innovation Awards, showcases breakthroughs in emergency drug delivery.

Read More